TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20490520

Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach (ALMI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Modified direct lateral approach (mDL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: mDL
Number of subjects: 44
Study: 18499604

Group type: EXPERIMENTAL
Intervention: Dex 0.2 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dex 0.4 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dex 0.8 microg x kg(‐1) x h(‐1) IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 80
Study: 16687898

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lead-induced obstruction in coronary sinus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac venous blood pumping conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal activation of left ventricle
Number of subjects: 0
Study: 14534370

Group type: EXPERIMENTAL
Intervention: Ginger root (1 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Misoprostol (400 microg)
Number of subjects: 22
Study: 10590490

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers (e.g., carvedilol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: EP guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 8698943

Group type: EXPERIMENTAL
Intervention: Transference-oriented approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transference focus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High QOR sample
Number of subjects: 60
Study: 1605660

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Norfloxacin (800 mg, orally QID)
Number of subjects: 73
Study: 6374774

Group type: COMPARATOR
Intervention: etidocaine 1.5% without a vasoconstrictor (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: etidocaine 1.5% with adrenaline 1:200,000 (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: etidocaine 1.5% with ornipressine 1 IU/10 ml (n = 10)
Number of subjects: 30
Study: 30591358

Group type: EXPERIMENTAL
Intervention: Sodium reduction program (education and access to reduced-sodium salt substitute)
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Control group (no sodium reduction program)
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Sodium reduction program
Number of subjects: 2566
Study: 30017346

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 27503474

Group type: EXPERIMENTAL
Intervention: Typhoid polysaccharide vaccine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 16
Study: 25252510

Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anaesthetics cream (2g applied to injection site)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rattle (shaken for 30s to 15s before injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anaesthetics cream
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rattle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 22149540

Group type: EXPERIMENTAL
Intervention: bidimensional-slot (bDS)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: bidimensional-wire (bDW)
Number of subjects: 76

Group type: COMPARATOR
Intervention: control
Number of subjects: 76
Study: 20876734

Group type: EXPERIMENTAL
Intervention: NT-proBNP guided therapy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Guideline-based treatment
Number of subjects: 252
Study: 18284057

Group type: EXPERIMENTAL
Intervention: Transurethral holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open prostatectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both HoLEP and open prostatectomy
Number of subjects: 60
Study: 16119401

Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement (< or = 10 cm)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard incision total hip replacement (16 cm)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard incision total hip replacement
Number of subjects: 219
Study: 12379391

Group type: EXPERIMENTAL
Intervention: Immediate active mobilisation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed mobilisation (5-day delay)
Number of subjects: 60
Study: 10027027

Group type: EXPERIMENTAL
Intervention: Dixyrazine 0.25 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7738924

Group type: EXPERIMENTAL
Intervention: Nonstress test (NST) during the 41st week of pregnancy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no NST)
Number of subjects: 300
Study: 2290245

Group type: EXPERIMENTAL
Intervention: Intervention group (received letter with colorectal cancer facts and Risk Appraisal)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (received letter stating availability of FOB test)
Number of subjects: 278
Study: 7015021

Group type: EXPERIMENTAL
Intervention: Minidose propranolol (5 to 10 mg/6 hr)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Propranolol postoperatively (not specified dosage)
Number of subjects: 85
Study: 30724634

Group type: EXPERIMENTAL
Intervention: Male firstness in academic writing
Number of subjects: 754

Group type: COMPARATOR
Intervention: Female firstness in academic writing
Number of subjects: 754
Study: 31106574

Group type: EXPERIMENTAL
Intervention: EasyWarm® self-heating blanket
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cocoon forced-air warming blanket
Number of subjects: 39
Study: 28853509

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 60
Study: 26378246

Group type: EXPERIMENTAL
Intervention: Caffeine consumption equivalent to a double espresso 3 hours before habitual bedtime
Number of subjects: 49

Group type: COMPARATOR
Intervention: Evening bright light exposure (3000 lux, 7 W/m(2))
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Caffeine (dose-dependent)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 49
Study: 22879443

Group type: EXPERIMENTAL
Intervention: Manual therapy and spine strengthening exercises
Number of subjects: 149
Study: 21884875

Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI)
Number of subjects: 14527

Group type: COMPARATOR
Intervention: eGFR(MDRD)
Number of subjects: 14527
Study: 20057194

Group type: EXPERIMENTAL
Intervention: Water consumption promotion intervention (water fountains installed, water bottles provided, classroom lessons conducted)
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Water consumption promotion intervention
Number of subjects: 2950
Study: 17130429

Group type: EXPERIMENTAL
Intervention: Carbamazepine as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate as monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate antiepileptic drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed antiepileptic drug treatment
Number of subjects: 0
Study: 15276508

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (n = 26)
Number of subjects: 52
Study: 11039455

Group type: EXPERIMENTAL
Intervention: 201Tl myocardial SPET with exercise (n = 9)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 201Tl myocardial SPET with dipyridamole stress (n = 13)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Group A (n = 10) with cardiac abnormalities on conventional testing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Group B (n = 12) without cardiac abnormalities on conventional testing
Number of subjects: 22
Study: 9292072

Group type: EXPERIMENTAL
Intervention: 1 alpha,25(OH)2D3 (calcitriol)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: KH 1060 (lexacalcitol)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Solution vehicles and empty chamber
Number of subjects: 42
Study: 8111209

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhizae and Polyporus Umbellatus polysaccharide (group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Salvia miltiorrhizae (group II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Polyporus Umbellatus polysaccharide (group III)
Number of subjects: 90
Study: 3518596

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (synthetic androgen) for 3 days before and on the day of chemotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cyclic chemotherapy with aminoglutethimide and hydrocortisone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stimulation group
Number of subjects: 57
Study: 31482511

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg qd
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 29934384

Group type: EXPERIMENTAL
Intervention: Low birth weight infants (LBW)
Number of subjects: 44984
Study: 25190537

Group type: EXPERIMENTAL
Intervention: Raising the bed head
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Using multiple pillows
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 24
Study: 22520267

Group type: EXPERIMENTAL
Intervention: Dose to the anal surface at 53 Gy
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Mean dose to the anal surface
Number of subjects: 388
Study: 19669773

Group type: EXPERIMENTAL
Intervention: Intracorporeal pneumatic shock therapy (IPST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inactive (placebo)
Number of subjects: 50
Study: 17558730

Group type: EXPERIMENTAL
Intervention: Diet and activity advice (low-fat, high-carbohydrate, sucrose-containing diet + 60 min/day brisk walking)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (including sucrose) energy-reduced diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: 60 min/day brisk walking
Number of subjects: 69
Study: 16178960

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 2
Study: 12227275

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (Verteporfin)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9863775

Group type: EXPERIMENTAL
Intervention: Pb glazing families (exposed to lead)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-Pb glazing families (not exposed to lead)
Number of subjects: 51
Study: 8550248

Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg/day for 2 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (2 months)
Number of subjects: 15
Study: 2693917

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (Estraderm)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 335279

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 50
Study: 31880370

Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (Kp10) injection (5 µg/kg body weight), administered intramuscularly once a week for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline-treated control group
Number of subjects: 0
Study: 30935545

Group type: EXPERIMENTAL
Intervention: Propolis (500 mg, three times a day for 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 29145288

Group type: EXPERIMENTAL
Intervention: Cold application (600-g ice packs for 15 minutes before CTR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment (tap water packs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both experimental and sham groups (men)
Number of subjects: 60
Study: 25990355

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 58
Study: 23053900

Group type: EXPERIMENTAL
Intervention: Mosapride (30 mg) plus esomeprazole (40 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus esomeprazole (40 mg)
Number of subjects: 50
Study: 21600117

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Transobturator tape (TVT-O)
Number of subjects: 315
Study: 18752430

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hepatitis A virus (HAV) vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (received TT vaccine first, then HAV vaccine)
Number of subjects: 46
Study: 15895329

Group type: EXPERIMENTAL
Intervention: Strength Training and Stretching (STG)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Stretching Alone (CG)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Strength Training (STG)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 126
Study: 12022799

Group type: EXPERIMENTAL
Intervention: Voucher (n = 29)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-voucher (n = 23)
Number of subjects: 52
Study: 10093094

Group type: EXPERIMENTAL
Intervention: ISAAC study (Brazil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portuguese Study (Cape Verde)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portuguese Study (Madeira)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portuguese Study (Macau)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchial challenge test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dust mite antigen analysis
Number of subjects: 0
Study: 7529468

Group type: EXPERIMENTAL
Intervention: Large-dose aprotinin (initial dose of 2,000,000 KIU followed by infusion of 500,000 KIU/h)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Small-dose aprotinin (initial dose of 500,000 KIU followed by infusion of 150,000 KIU/h)
Number of subjects: 199
Study: 1697836

Group type: EXPERIMENTAL
Intervention: 1 deamino‐8‐D‐arginine vasopressin (DDAVP) 0.4 micrograms/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 396657

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30955089

Group type: COMPARATOR
Intervention: Traditional (TR: 6 sets of 4 repetitions with 3 min of rest between sets)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cluster (CL: 6 sets of 4 repetitions with 15 s of intra-set rest every two repetitions and 2 min and 45 s of rest between sets)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inter-repetition rest (IRR: 1 set of 24 repetitions with 39 s of rest between repetitions)
Number of subjects: 26
Study: 28712353

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention for PTSD (CBT-P), 12-16 sessions
Number of subjects: 183

Group type: COMPARATOR
Intervention: Breathing retraining and psychoeducation intervention (BRF), 3 sessions
Number of subjects: 183
Study: 25999100

Group type: EXPERIMENTAL
Intervention: Early aggressive strategy
Number of subjects: 645

Group type: COMPARATOR
Intervention: Initially conservative strategy
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 645

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 645
Study: 22237990

Group type: EXPERIMENTAL
Intervention: Seating force of 10 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Seating force of 50 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Seating force of 100 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Seating force of 500 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Seating force of 750 g
Number of subjects: 45
Study: 21671496

Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g, bismuth potassium citrate 220 mg for 7 days)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard triple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g for 7 days)
Number of subjects: 136
Study: 19086083

Group type: EXPERIMENTAL
Intervention: Early-start rasagiline treatment
Number of subjects: 404

Group type: COMPARATOR
Intervention: Delayed-start rasagiline treatment (placebo for 6 months)
Number of subjects: 404
Study: 16725133

Group type: EXPERIMENTAL
Intervention: Fluorescent polarization immunoassay (FPIA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: HPLC-tandem mass spectrometry (HPLC-MS)
Number of subjects: 45
Study: 15833263

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 3
Study: 12077522

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid formulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5% ascorbyl glucosamine, 1% kojic acid and alpha‐hydroxyacid esters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stabilized soy extract
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical whitening agents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subclinical or faint mottled skin
Number of subjects: 50
Study: 10465378

Group type: EXPERIMENTAL
Intervention: Transdermal gel (1.5 mg oestradiol)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tablet (2 mg oestradiol valerate)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transdermal patch (50 microg/24 h)
Number of subjects: 27
Study: 8667576

Group type: EXPERIMENTAL
Intervention: Collagen and autologous growth factors
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 35
Study: 2356715

Group type: COMPARATOR
Intervention: Compression applied for 10 minutes (C-10)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compression applied for 20 minutes (C-20)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No compression (Control group)
Number of subjects: 100
Study: 475944

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide (0.3 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 30080727

Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Abdominal Wound Catheters plus Patient-Controlled Analgesia (AWC-PCA)
Number of subjects: 83
Study: 28806502

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no ESS)
Number of subjects: 26
Study: 25251893

Group type: EXPERIMENTAL
Intervention: Remifentanil alone (group-R)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Midazolam-meperidine combination (group-MM)
Number of subjects: 54
Study: 23782589

Group type: EXPERIMENTAL
Intervention: 6 g/day of fish oil (approximately 3.6 g/day of LCn‐3PUFA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 6 g/day of corn oil (placebo)
Number of subjects: 40
Study: 21717779

Group type: EXPERIMENTAL
Intervention: Acupuncture of Ashi-points plus moxibustion of heat-sensitive points
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acupuncture of Ashi-points plus TDP irradiation
Number of subjects: 62
Study: 19207321

Group type: EXPERIMENTAL
Intervention: Large-particle NASHA filler
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Small-particle NASHA filler
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Fanning injection technique
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Volume of NASHA product used
Number of subjects: 248
Study: 17161821

Group type: EXPERIMENTAL
Intervention: FTY720 (0.25-2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTY720 (3.5 mg)
Number of subjects: 0
Study: 15060237

Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program (NIDCAP) initiated within 72 hours of ICU admission and continued to 2 weeks corrected for prematurity.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study: 11495165

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study: 9920537

Group type: EXPERIMENTAL
Intervention: Norgestimate and ethinyl estradiol (0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) for 3 weeks followed by 1 week of inactive tablets
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo tablets for 4 weeks
Number of subjects: 507
Study: 7551066

Group type: EXPERIMENTAL
Intervention: Personalized Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2972549

Group type: EXPERIMENTAL
Intervention: Cetirizine di-HCl (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dexchlorpheniramine maleate (6 mg)
Number of subjects: 12
Study: 31640794

Group type: EXPERIMENTAL
Intervention: IPF patients
Number of subjects: 300
Study: 30207100

Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver (PRM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 27454785

Group type: EXPERIMENTAL
Intervention: VMS-ASIR in DE-CTPA group
Number of subjects: 140